Report Overview
Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016, provides an overview of the Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline landscape.
Dry atrophic macular degeneration is generally characterized by a slow but progressive visual loss. This is characterized by yellow spots under the retina, called drusen, which are accumulations of metabolic waste products. Symptoms include blurred or decreased central close-up and distance vision, blind spots, micropsia and straight lines look distorted. Predisposing factors include age and family history.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 2, 14, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Dry (Atrophic) Macular Degeneration.
Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table Of Contents
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Dry (Atrophic) Macular Degeneration Overview 11
Therapeutics Development 12
Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview 12
Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis 13
Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies 14
Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 16
Dry (Atrophic) Macular Degeneration - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Dry (Atrophic) Macular Degeneration - Products under Development by Companies 21
Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes 23
Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development 24
Aciont Inc. 24
Alimera Sciences, Inc. 25
Allergan Plc 26
Apellis Pharmaceuticals Inc 27
Astellas Pharma Inc. 28
Benitec Biopharma Limited 29
Biophytis SAS 30
Catalyst Biosciences, Inc. 31
Cell Cure Neurosciences, Ltd. 32
Charlesson LLC. 33
Foamix Pharmaceuticals Ltd. 34
Genentech Inc 35
GenSight Biologics S.A. 36
GlaxoSmithKline Plc 37
Icon Bioscience, Inc. 38
Inception Sciences, Inc. 39
Johnson & Johnson 40
Kodiak Sciences Inc. 41
MacuCLEAR Inc 42
MeiraGTx Limited 43
Novartis AG 44
Ophthotech Corp. 45
Orphagen Pharmaceuticals, Inc. 46
pSivida Corp. 47
Samumed LLC 48
Sucampo Pharmaceuticals, Inc. 49
Sun Pharma Advanced Research Co Ltd 50
Dry (Atrophic) Macular Degeneration - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 54
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
A-005 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
APL-2 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
avacincaptad pegol sodium - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
BBAMD-231 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
BIO-201 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
brimonidine tartrate implant - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
CLG-561 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
CLT-005 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
CNTO-2476 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Drug for Age Related Macular Degeneration - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
EG-30 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
FMX-103 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Gene Therapy for Ocular Diseases - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
GS-030 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
GSK-933776 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
ICR-14967 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
KSI-401 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
lampalizumab - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
MA09-hRPE - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
MC-1101 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
methotrexate - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
OCU-100 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
ONL-1204 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
OpRegen - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
OpRegen Plus - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
RC-1 Alpha - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
RST-001 - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
Small Molecule for Dry AMD and Wet AMD - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
Small Molecules for AMD - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
Small Molecules for Dry Age-Related Macular Degeneration - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
Small Molecules for Dry AMD - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
tesidolumab - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
unoprostone isopropyl - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
VM-100 - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
Dry (Atrophic) Macular Degeneration - Dormant Projects 121
Dry (Atrophic) Macular Degeneration - Discontinued Products 124
Dry (Atrophic) Macular Degeneration - Product Development Milestones 125
Featured News & Press Releases 125
Aug 30, 2016: RetroSense Therapeutics Granted Patent on Proprietary Method for Restoring Vision using Optogenetics 125
May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences 125
Apr 12, 2016: BIOPHYTIS to Present Pre-Clinical Data on BIO 201 at Upcoming Scientific Conference 126
Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia 126
Oct 01, 2013: Roche to present data on Lampalizumab at investor event 127
Aug 27, 2013: Roche’s lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration 127
Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials 128
May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells 129
Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt’s Macular Dystrophy 129
Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy 130
Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells 131
Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference 132
Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone 132
Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells 133
Aug 02, 2012: ACT Announces First Dry Age-Related Macular Degeneration Patient Treated With Higher Dosage Of Embryonic Stem Cell-Derived RPE Cells 134
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 135
Disclaimer 136
List Of Tables
List of Tables
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016 12
Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Comparative Analysis by Unknown Stage Development, H2 2016 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2016 23
Dry (Atrophic) Macular Degeneration - Pipeline by Aciont Inc., H2 2016 24
Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H2 2016 25
Dry (Atrophic) Macular Degeneration - Pipeline by Allergan Plc, H2 2016 26
Dry (Atrophic) Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H2 2016 27
Dry (Atrophic) Macular Degeneration - Pipeline by Astellas Pharma Inc., H2 2016 28
Dry (Atrophic) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016 29
Dry (Atrophic) Macular Degeneration - Pipeline by Biophytis SAS, H2 2016 30
Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H2 2016 31
Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H2 2016 32
Dry (Atrophic) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016 33
Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 34
Dry (Atrophic) Macular Degeneration - Pipeline by Genentech Inc, H2 2016 35
Dry (Atrophic) Macular Degeneration - Pipeline by GenSight Biologics S.A., H2 2016 36
Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2016 37
Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016 38
Dry (Atrophic) Macular Degeneration - Pipeline by Inception Sciences, Inc., H2 2016 39
Dry (Atrophic) Macular Degeneration - Pipeline by Johnson & Johnson, H2 2016 40
Dry (Atrophic) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016 41
Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR Inc, H2 2016 42
Dry (Atrophic) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016 43
Dry (Atrophic) Macular Degeneration - Pipeline by Novartis AG, H2 2016 44
Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016 45
Dry (Atrophic) Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 46
Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H2 2016 47
Dry (Atrophic) Macular Degeneration - Pipeline by Samumed LLC, H2 2016 48
Dry (Atrophic) Macular Degeneration - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 49
Dry (Atrophic) Macular Degeneration - Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016 50
Assessment by Monotherapy Products, H2 2016 51
Number of Products by Stage and Target, H2 2016 53
Number of Products by Stage and Mechanism of Action, H2 2016 55
Number of Products by Stage and Route of Administration, H2 2016 57
Number of Products by Stage and Molecule Type, H2 2016 59
Dry (Atrophic) Macular Degeneration - Dormant Projects, H2 2016 121
Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..1), H2 2016 122
Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..2), H2 2016 123
Dry (Atrophic) Macular Degeneration - Discontinued Products, H2 2016 124
List Of Figures
List of Figures
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016 12
Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Products, H2 2016 19
Assessment by Monotherapy Products, H2 2016 51
Number of Products by Top 10 Targets, H2 2016 52
Number of Products by Stage and Top 10 Targets, H2 2016 52
Number of Products by Top 10 Mechanism of Actions, H2 2016 54
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 54
Number of Products by Routes of Administration, H2 2016 56
Number of Products by Stage and Routes of Administration, H2 2016 56
Number of Products by Top 10 Molecule Types, H2 2016 58
Number of Products by Stage and Top 10 Molecule Types, H2 2016 58